Improvements and correlations in oral ulcers, disease activity, and quality of life in Behçet syndrome patients treated with apremilast: A phase III randomized, double-blind, placebo-controlled study (RELIEF) - 22/08/19
Gülen Hatemi, Istanbul University Cerrahpasa Medical School, Istanbul, Turkey; Alfred Mahr, Hospital Saint-Louis, University Paris Diderot, Paris, France; Mitsuhiro Takeno, Nippon Medical School, Graduate School of Medicine, Tokyo, Japan; Do-Young Kim, Yonsei University College of Medicine and Severance Hospital, Seoul, South Korea; Melike Melikoglu, Istanbul University Cerrahpasa Medical School, Istanbul, Turkey; Sue Cheng, Celgene Corporation, Summit, NJ; Shannon McCue, Celgene Corporation, Summit, NJ; Maria Paris, Celgene Corporation, Summit, NJ; Mindy Chen, Celgene Corporation, Summit, NJ; Yusuf Yazici, New York University School of Medicine, New York, NY
Le texte complet de cet article est disponible en PDF.| Supported by Celgene Corporation. |
Vol 81 - N° 4S1
P. AB78 - octobre 2019 Retour au numéro
Article précédent
- Improvement of itch and pain in patients with prurigo nodularis treated with serlopitant: Secondary analysis of phase 2 clinical trial
- Improvements in efficacy and lesion quality in scalp plaque psoriasis with fixed combination calcipotriene and betamethasone dipropionate (Cal/BD) foam treatment
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?